Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

uthorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

PhenoSense, PhenoSenseGT, Trofile, HERmark and VeraTag are trademarks of Monogram Biosciences, Inc. Heceptin is a registered trademark of Genentech, Inc. Selzentry is a trademark and Celsentri is a registered trademark of Pfizer Inc. - financials to follow - MONOGRAM BIOSCIENCES, INC. SELECTED STATEMENT OF OPERATIONS DATA (In thousands, except per share amounts) (Unaudited)

Three Months Ended Nine Months Ended

Septemb
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of Nidea ... new development in Downtown Toronto is expanding at a ... 755 storeys of new development last week (including three ... dominating the Toronto skyline for the foreseeable future in ... for new development. , As the Toronto city council ...
(Date:9/15/2014)... phase transitionsthink solid, liquid, and gasbut much ... drops. If phase transitions occur at the ... subtle fluctuations can dramatically transform a material. ... of Energy,s Brookhaven National Laboratory and Stony ... of absolute zero to isolate and probe ...
(Date:9/15/2014)... 16, 2014 Cancer Immunotherapy ... Adoptive T-cell Therapies is a new market research ... the three principal types of therapeutics that have ... in cancer immunotherapy (which is often called "immuno-oncology") ... and Adoptive cellular immunotherapy. , The regular ...
(Date:9/15/2014)... Calif. , Sept. 15, 2014  FlexTech ... (RFP) for flexible, printed product demonstrators (demos) and ... two-stage RFP process with pre-proposals due on October ... 2015.  Funds for proposals ultimately selected are provided ... have a significant cost share by the proposing ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3Elusive quantum transformations found near absolute zero 2Elusive quantum transformations found near absolute zero 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2
... Thermo Fisher,Scientific Inc. (NYSE: TMO ) announced ... president and chief executive,officer, are adopting stock- trading ... covering the future sale of company stock. Mr.,Dekkers, ... over August,15-17, 2007, has adopted a plan for ...
... Pharmion - ... - Sirtuins implicated in tumor ... combination epigenetic therapies, BOULDER, Colo. and MONTREAL, Aug. 20 ... MYG) today announced a,research collaboration for the development of novel ...
... CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group ... second quarter of 2007 increased more than,35% over the ... times,revenues of just $13,351 for the same period in ... of 2007 were $3,256,000 compared to only,$24,374 in the ...
Cached Biology Technology:Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:9/16/2014)... us sick can take up residence in and on ... other troublesome symptom, according to new research at Washington ... On average, healthy individuals carry about five types of ... BioMed Central Biology . The study is the ... in healthy people. , The research was conducted ...
(Date:9/16/2014)... dinosaurs 66 million years ago decimated the evergreens among ... their deciduous peers, according to a study led by ... PLOS Biology . , Applying biomechanical formulas ... of angiosperms flowering plants excluding conifers ... a diverse plant community thriving during a 2.2 million-year ...
(Date:9/16/2014)... fall marks a new school year, a new football ... Space Station. In September, SpaceX,s Dragon spacecraft is scheduled ... and investigations as part of the company,s fourth contracted ... will be the third suite of research investigations sponsored ... Space (CASIS). With the role of managing the U.S. ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... sexy (especially when scientists start analyzing it), but it is ... an egg and a sperm, a whole lot of cell ... that carries a mix of genes from both parents. There ... the most fundamental and important is the transition from unfertilized ...
... new drug has been shown to improve blood flow in ... heart attacks, a Monash University study published today reveals. , ... that, in conjunction with Bayer Health Care, hopes to use ... of heart disease. , Dr. Harald Schmidt, Director of the ...
... men age 40 and older have a significantly increased ... whose fathers are younger than 30 years, according to ... General Psychiatry, one of the JAMA/Archives journals. , Autism ... patterns of behavior, according to background information in the ...
Cached Biology News:Cracking the egg 2Heart smart: new drug improves blood flow 2Older fathers more likely to have autistic children 2
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... NEW HandyStep electronic from BRAND adds ... It is the only electronic, motor-driven ... syringe tips, including BRAND PD-Tip syringe ... Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. Select ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Biology Products: